September 8, 2017September 8, 2017

miRagen Therapeutics to Present New Promising Data on MRG-201 at ERS 2017

miRagen Therapeutics, a biopharmaceutical company involved in the discovery of RNA-based therapies, will present new preclinical safety and feasibility data for the therapy MRG-201 in the treatment of pulmonary fibrosis at the ... Read more

April 28, 2017April 28, 2017

Phase 1 Interim Trial Results of miRagen’s Anti-Fibrotic Therapy Show Potential

Idiopathic Pulmonary Fibrosis, News

Initial results from a Phase 1 study on miRagen Therapeutics‘ investigative drug MRG-201 on healthy volunteers show potential for fibrous scar tissue in certain diseases. The company announced it will present ... Read more